Silvina Arrossi1, Sarah Temin1, Suzanne Garland1, Linda O'Neal Eckert1, Neerja Bhatla1, Xavier Castellsagué1, Sharifa Ezat Alkaff1, Tamika Felder1, Doudja Hammouda1, Ryo Konno1, Gilberto Lopes1, Emmanuel Mugisha1, Rául Murillo1, Isabel C Scarinci1, Margaret Stanley1, Vivien Tsu1, Cosette M Wheeler1, Isaac Folorunso Adewole1, Silvia de Sanjosé1. 1. , Instituto Nacional del Cancer, Buenos Aires, Argentina; , American Society of Clinical Oncology, Alexandria, VA; , University of Melbourne, Melbourne, Victoria, Australia; , University of Washington; , PATH, Seattle, WA; , All India Institute of Medical Sciences, New Delhi, India; and , Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain; , Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia; , Cervivor, Upper Marlboro, MD; , Institut National de Santé Publique, Algiers, Algeria; , Jichi Medical University, Saitama Medical Center, Saitama, Japan; , Sylvester Comprehensive Cancer Center, Miami, FL; , PATH, Kampala, Uganda; , International Agency for Research on Cancer, Lyon, France; , University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; , University of Cambridge, Cambridge, United Kingdom; , University of New Mexico, Albuquerque, NM; and , Ministry of Health, Abuja, Nigeria.
Abstract
PURPOSE: To provide resource-stratified (four tiers), evidence-based recommendations on the primary prevention of cervical cancer globally. METHODS: The American Society of Clinical Oncology convened a multidisciplinary, multinational panel of oncology, obstetrics/gynecology, public health, cancer control, epidemiology/biostatistics, health economics, behavioral/implementation science, and patient advocacy experts. The Expert Panel reviewed existing guidelines and conducted a modified ADAPTE process and a formal consensus-based process with additional experts (consensus ratings group) for one round of formal ratings. RESULTS: Existing sets of guidelines from five guideline developers were identified and reviewed; adapted recommendations formed the evidence base. Five systematic reviews, along with cost-effectiveness analyses, provided evidence to inform the formal consensus process, which resulted in agreement of ≥ 75%. RECOMMENDATIONS: In all resource settings, two doses of human papillomavirus vaccine are recommended for girls age 9 to 14 years, with an interval of at least 6 months and possibly up to 12 to 15 months. Individuals with HIV positivity should receive three doses. Maximal and enhanced settings: if girls are age ≥ 15 years and received their first dose before age 15 years, they may complete the series; if no doses were received before age 15 years, three doses should be administered; in both scenarios, vaccination may be through age 26 years. Limited and basic settings: if sufficient resources remain after vaccinating girls age 9 to 14 years, girls who received one dose may receive additional doses between age 15 and 26 years. Maximal, enhanced, and limited settings: if ≥ 50% coverage in the priority female target population, sufficient resources, and cost effectiveness, boys may be vaccinated to prevent other noncervical human papillomavirus-related cancers and diseases. Basic settings: vaccinating boys is not recommended. It is the view of the American Society of Clinical Oncology that health care providers and health care system decision makers should be guided by the recommendations for the highest stratum of resources available. The guideline is intended to complement but not replace local guidelines.
PURPOSE: To provide resource-stratified (four tiers), evidence-based recommendations on the primary prevention of cervical cancer globally. METHODS: The American Society of Clinical Oncology convened a multidisciplinary, multinational panel of oncology, obstetrics/gynecology, public health, cancer control, epidemiology/biostatistics, health economics, behavioral/implementation science, and patient advocacy experts. The Expert Panel reviewed existing guidelines and conducted a modified ADAPTE process and a formal consensus-based process with additional experts (consensus ratings group) for one round of formal ratings. RESULTS: Existing sets of guidelines from five guideline developers were identified and reviewed; adapted recommendations formed the evidence base. Five systematic reviews, along with cost-effectiveness analyses, provided evidence to inform the formal consensus process, which resulted in agreement of ≥ 75%. RECOMMENDATIONS: In all resource settings, two doses of human papillomavirus vaccine are recommended for girls age 9 to 14 years, with an interval of at least 6 months and possibly up to 12 to 15 months. Individuals with HIV positivity should receive three doses. Maximal and enhanced settings: if girls are age ≥ 15 years and received their first dose before age 15 years, they may complete the series; if no doses were received before age 15 years, three doses should be administered; in both scenarios, vaccination may be through age 26 years. Limited and basic settings: if sufficient resources remain after vaccinating girls age 9 to 14 years, girls who received one dose may receive additional doses between age 15 and 26 years. Maximal, enhanced, and limited settings: if ≥ 50% coverage in the priority female target population, sufficient resources, and cost effectiveness, boys may be vaccinated to prevent other noncervical human papillomavirus-related cancers and diseases. Basic settings: vaccinating boys is not recommended. It is the view of the American Society of Clinical Oncology that health care providers and health care system decision makers should be guided by the recommendations for the highest stratum of resources available. The guideline is intended to complement but not replace local guidelines.
Authors: Cosette M Wheeler; Xavier Castellsagué; Suzanne M Garland; Anne Szarewski; Jorma Paavonen; Paulo Naud; Jorge Salmerón; Song-Nan Chow; Dan Apter; Henry Kitchener; Júlio C Teixeira; S Rachel Skinner; Unnop Jaisamrarn; Genara Limson; Barbara Romanowski; Fred Y Aoki; Tino F Schwarz; Willy A J Poppe; F Xavier Bosch; Diane M Harper; Warner Huh; Karin Hardt; Toufik Zahaf; Dominique Descamps; Frank Struyf; Gary Dubin; Matti Lehtinen Journal: Lancet Oncol Date: 2011-11-08 Impact factor: 41.316
Authors: Suzanne M Garland; Asvini K Subasinghe; Yasmin L Jayasinghe; John D Wark; Anna-Barbara Moscicki; Albert Singer; Xavier Bosch; Karen Cusack; Margaret Stanley Journal: Lancet Date: 2015-11-13 Impact factor: 79.321
Authors: Howard H Bailey; Linus T Chuang; Nefertiti C duPont; Cathy Eng; Lewis E Foxhall; Janette K Merrill; Dana S Wollins; Charles D Blanke Journal: J Clin Oncol Date: 2016-04-11 Impact factor: 44.544
Authors: Mélanie Drolet; Élodie Bénard; Marie-Claude Boily; Hammad Ali; Louise Baandrup; Heidi Bauer; Simon Beddows; Jacques Brisson; Julia M L Brotherton; Teresa Cummings; Basil Donovan; Christopher K Fairley; Elaine W Flagg; Anne M Johnson; Jessica A Kahn; Kimberley Kavanagh; Susanne K Kjaer; Erich V Kliewer; Philippe Lemieux-Mellouki; Lauri Markowitz; Aminata Mboup; David Mesher; Linda Niccolai; Jeannie Oliphant; Kevin G Pollock; Kate Soldan; Pam Sonnenberg; Sepehr N Tabrizi; Clare Tanton; Marc Brisson Journal: Lancet Infect Dis Date: 2015-03-03 Impact factor: 25.071
Authors: Thanyawee Puthanakit; Li-Min Huang; Cheng-Hsun Chiu; Ren-Bin Tang; Tino F Schwarz; Susanna Esposito; Louise Frenette; Carlo Giaquinto; Shelly McNeil; Paul Rheault; Paolo Durando; Michael Horn; Maximilian Klar; Sylviane Poncelet; Stéphanie De Simoni; Damien Friel; Benoit De Muynck; Pemmaraju V Suryakiran; Marjan Hezareh; Dominique Descamps; Florence Thomas; Frank Struyf Journal: J Infect Dis Date: 2016-02-03 Impact factor: 5.226
Authors: Leonardo Miranda Dos Santos; Josiellem Damasceno de Souza; Hilary Acha Mbakwa; Akim Felipe Santos Nobre; Rodrigo Covre Vieira; Stephen Francis Ferrari; Anderson Raiol Rodrigues; Edna Aoba Yassui Ishikawa; João Farias Guerreiro; Maísa Silva de Sousa Journal: PLoS One Date: 2022-07-18 Impact factor: 3.752
Authors: Sana Al-Sukhun; Sarah Temin; Mariana Chavez-MacGregor; Neelima Denduluri; Thomas K Oliver; Doug Pyle; Manish A Shah; Julie Gralow Journal: J Glob Oncol Date: 2018-07
Authors: Sara Villanueva; Diego Gabriel Mosteiro-Miguéns; Eva María Domínguez-Martís; David López-Ares; Silvia Novío Journal: Int J Environ Res Public Health Date: 2019-11-15 Impact factor: 3.390
Authors: Rashidul Alam Mahumud; Syed Afroz Keramat; Gail M Ormsby; Marufa Sultana; Lal B Rawal; Khorshed Alam; Jeff Gow; Andre M N Renzaho Journal: Int J Equity Health Date: 2020-03-26